- Spain CIMA (Spanish): search for “teicoplanin” (external search; text not reproduced)
External search; text not reproduced. Check the Philippine package insert in the products table.
Contraindications
- Hypersensitivity to teicoplanin
Dosing: Adult
- Complicated skin and soft tissue infection, pneumonia, complicated urinary tract infection: Loading 6 mg/kg IV or IM every 12 hours for 3 doses, then 6 mg/kg once daily
- Bone and joint infection: Loading 12 mg/kg IV every 12 hours for 3 to 5 doses, then 12 mg/kg once daily
- Infective endocarditis: Loading 12 mg/kg IV every 12 hours for 3 to 5 doses, then 12 mg/kg once daily; usually at least 21 days
- Clostridioides difficile diarrhea (oral): 100 to 200 mg orally twice daily for 7 to 14 days
Dosing: Altered kidney function
Teicoplanin is a glycopeptide excreted about 80% unchanged in urine, with a very long terminal half-life (100 to 170 hours). The European label gives the full loading dose, then from day 4 halves the maintenance dose at creatinine clearance (CrCl) 30–80 mL/min and gives one-third at CrCl below 30 mL/min and on hemodialysis, guided by trough levels. Hemodialysis does not remove it. It has no US FDA label.
Kidney function measure: European summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min); thresholds 80 and 30.
Show full dosing details
- CrCl ≥60 mL/min
- CrCl >80: usual loading and maintenance doses (e.g., 6 mg/kg every 12 hours for 3 doses, then 6 mg/kg once daily; 12 mg/kg for bone, joint and endocarditis). CrCl 60–80: no change until day 4, then half the maintenance dose (full dose every 2 days or half dose daily) (SmPC).
- CrCl 30–59 mL/min
- Usual loading doses; from day 4, half the maintenance dose: the full dose every 2 days or half the dose once daily (SmPC: CrCl 30–80). Keep trough at least 15 mg/L (FPIA) or 10 mg/L (HPLC).
- CrCl 15–29 mL/min
- Usual loading doses; from day 4, one-third of the maintenance dose: the full dose every 3 days or one-third once daily (SmPC: CrCl <30). Guide by trough levels.
- CrCl <15 mL/min (not on dialysis)
- Usual loading doses; from day 4, one-third of the maintenance dose (full dose every 3 days or one-third daily) (SmPC). Guide by trough levels.
- Hemodialysis (intermittent)
- As for CrCl <30: usual loading, then one-third of the maintenance dose from day 4 (every third day or one-third daily). Not removed by hemodialysis; no supplement needed (SmPC).
- Peritoneal dialysis
- CAPD peritonitis: single intravenous loading dose of 6 mg/kg, then 20 mg/L in the dialysate: week 1 in every bag; week 2 in alternate bags; week 3 in the overnight bag only (SmPC). Removed only slowly by peritoneal dialysis.
- CRRT
- No CRRT dosing in the SmPC. Use trough-guided dosing; specialist input.
- Dialyzable? No: not removed by hemodialysis; removed only slowly by peritoneal dialysis (SmPC 4.2, 4.9).
- Monitoring Trough concentrations at steady state after loading and at least weekly during maintenance (trough targets by FPIA: at least 15 mg/L for complicated skin and soft-tissue infection, pneumonia and complicated urinary tract infection; above 20 mg/L for bone and joint infection; 30–40 mg/L after loading and above 30 mg/L during maintenance for endocarditis). In kidney impairment, set the day-4 reduction by trough rather than by CrCl alone. Kidney function closely in CKD, after high loading doses and with nephrotoxic drugs. Hearing tests with ototoxic or nephrotoxic co-medication. Blood counts periodically (SmPC 4.4).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Normal kidney function: usual weight-based doses (SmPC).
- eGFR 30–59
- No pediatric-specific kidney adjustment in the SmPC; adult principle (reduce maintenance from day 4, trough-guided) is a reasonable guide. Specialist input.
- eGFR 15–29
- No pediatric-specific kidney adjustment in the SmPC; adult principle (reduce maintenance from day 4, trough-guided) is a reasonable guide. Specialist input.
- eGFR <15 (not on dialysis)
- No pediatric-specific kidney adjustment in the SmPC; adult principle (reduce maintenance from day 4, trough-guided) is a reasonable guide. Specialist input.
- Hemodialysis (intermittent)
- No pediatric data; trough-guided specialist dosing.
- Peritoneal dialysis
- No pediatric data; trough-guided specialist dosing.
- CRRT
- No pediatric data; trough-guided specialist dosing.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: MPA (Sweden) product information (December 11, 2025). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- All ages, from neonates (SmPC).
- Usual dose
- Neonates and infants up to 2 months: 16 mg/kg intravenously on day 1, then 8 mg/kg once daily (infusion only). 2 months to 12 years: 10 mg/kg every 12 hours for 3 doses, then 6 to 10 mg/kg once daily. Over 12 years: adult doses (SmPC).
Pediatric half-life about 40 hours in neonates and 58 hours at a mean age of 8 years.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Lyophilized powder for injection: 200 mg, 400 mg
- Powder for injection: 200 mg, 400 mg
- Lyophilized powder for solution for injection: 200 mg, 400 mg
- Lyophilized powder for solution for injection/infusion: 200 mg, 400 mg
- Powder for injection ): 200 mg
- Powder for solution for injection: 400 mg
Registered products in the Philippines
15 products registered with the Food and Drug Administration (FDA) Philippines list Teicoplanin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products15
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Brutio 200Teicoplanin | 200 mg Lyophilized Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial with Yellow Flip-Off Seal (Box of 1's) | Rx | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-14945 | May 23, 2031 | |
Brutio 400Teicoplanin | 400 mg Lyophilized Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial with Orange Flip-Off Seal (Box of 1's) | Rx | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-14944 | May 23, 2031 | |
CamillaninTeicoplanin | 200 mg Lyophilized Powder for Solution for Injection (IM/IV)10mL-Capacity Type I Clear Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Purple Flip-Off Cap x 1's (Box of 1's) | Rx | Sichuan Huiyu Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-17581 | Feb 4, 2032 | |
CamillaninTeicoplanin | 400 mg Lyophilized Powder for Solution for Injection (IM/IV)20mL-Capacity Type I Clear Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Orange Flip-Off Cap x 1's (Box of 1's) | Rx | Sichuan Huiyu Pharmaceutical Co. Ltd.China | AMB HK Enterprises, Inc. | DRP-17582 | Feb 4, 2032 | |
ImtecTeicoplanin | 400 mg Lyophilized Powder for Injection (I.M./I.V.)In a box containing: 10 mL USP type I flint tubular glass vial with bromobutyl rubber slotted and red Alu flip-off seal + 5 mL USP type I ampoule (Sterilized Water for Injection as diluent) Box of 1's | Rx | Gufic Biosciences Ltd.India | Philcare Pharma Inc.Importer: SRS Life Sciences Inc. | DR-XY45058 | Feb 23, 2031 | |
PlanicidTeicoplanin | 400mg Lyophilized Powder for Injection (IM/IV)20 mL-capacity Type I clear glass vial with aluminum flip off cap and bromobutyl rubber stopper (Box of 1's) | Rx | Centurion İlaç Sanayi ve Ticaret A.Ş. Ankara ŞubesiTurkey | Stangen Pharmaceuticals Philippines Inc. | DRP-12851 | Oct 14, 2027 | |
TeclotanTeicoplanin | 200 mg Powder for Injection (IM/IV)Type II glass vial, with grey bromobutyl rubber stopper, aluminum seal and yellow PP flip-off cap (Box) | Rx | Venus Remedies LimitedIndia | Despina Pharma Inc. | DRP-16726 | Jul 1, 2030 | |
TeclotanTeicoplanin | 400 mg Powder for Injection (IM/IV)Type II glass vial, with grey bromobutyl rubber stopper, aluminum seal and blue PP flip-off cap (Box of 1's) | Rx | Venus Remedies LimitedIndia | Despina Pharma Inc. | DRP-16725 | Jul 1, 2030 | |
Teiconova-400Teicoplanin | 400 mg Powder for Solution for Injection (IM/IV)20 mL-capacity USP Type I clear colorless glass vial + 3 mL USP Type I colorless glass ampoule (Sterile water for injection as solvent) [Box of 1's] | Rx | Dongkook Pharmaceutical Co., Ltd.Korea | Medinova Pharmaceutical Inc. | DRP-15034 | Mar 21, 2029 | |
TeicopixTeicoplanin | 200 mg Lyophilized Powder for solution for Injection/InfusionPh. Eur. Type I clear and colorless glass vial with dark gray bromobutyl rubber stopper and aluminum seal with green polypropylene flip-off cap + 3 mL Water for Injection (as solvent) in Ph. Eur. Type I clear and colorless glass ampoule (Box of 1's and 5's) | Rx | Lek Pharmaceuticals d.d.Slovenia | Importer: Sandoz Philippines Corporation | DRP-13389 | Feb 10, 2028 | |
TeicopixTeicoplanin | 400 mg Lyophilized Powder for solution for Injection/InfusionPh. Eur. Type I clear and colorless glass vial with dark. gray bromobutyl rubber stopper and aluminum seal with blue polypropylene flip-off cap + 3 mL Water for Injection (as solvent) in Ph. Eur. Type I clear and colorless glass ampoule (Box of 1's and 5's) | Rx | Lek Pharmaceuticals d.d.Slovenia | Importer: Sandoz Philippines Corporation | DRP-13390 | Feb 10, 2028 | |
Teicotan 200Teicoplanin | 200 mg Lyophilized Powder for Injection (IM/IV)USP Type I flint glass tubular vial (as active) + USP Type I clear transparent ampoule x 5 mL (as diluent) in a plastic tray | Rx | Gufic Biosciences LimitedIndia | SRS Life Sciences Inc. | DR-XY43894 | Nov 13, 2029 | |
TicorayTeicoplanin | 200mg Powder For Injection (IV/IM))10 mL USP Type I glass vial with dark grey bromobutyl stopper and aluminum flip-off seal (Box of 1’s) | Rx | Mylan Laboratories Limited (Sterile Products Division)India | Mylan Philippines Inc | DR-XY48156 | Jul 1, 2027 | |
TicorayTeicoplanin | 400mg Powder For Injection (IV/IM)20 mL USP type I glass vial with dark grey bromobutyl stopper and aluminum flip-off seal (Box of 1’s) | Rx | Mylan Laboratories Limited (Sterile Products Division)India | Mylan Philippines Inc. | DR-XY48161 | Jul 4, 2027 | |
VellaninTeicoplanin | 400 mg Powder for Injection (I.M./I.V.)6 mL-capacity Type I clear and colorless glass vial with gray Type I rubber stopper and aluminum seal with orange PP flip-off cap (Box of 1's) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare, Inc. | DR-XY47721 | Feb 11, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Aminoglycosides, colistin, amphotericin B, cyclosporine, cisplatin, loop diuretics (furosemide, ethacrynic acid) | Adjust or monitor | Additive nephrotoxicity or ototoxicity. | Use with care; monitor kidney function and hearing. |
| Aminoglycosides (same syringe or bag) | Minor | Physically incompatible for injection. | Do not mix (compatible in CAPD fluid). |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Rash, erythema, pruritus
- Pain, fever
Serious
- Nephrotoxicity and acute kidney failure (about 2% on standard loading; 11% to 27% with high loading regimens)
- Ototoxicity: deafness, tinnitus, vestibular disorder
- Agranulocytosis, neutropenia, thrombocytopenia
- Anaphylaxis, red man syndrome
- Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, acute generalized exanthematous pustulosis
- Seizures
Monitoring parameters
- Trough concentrations at steady state after loading and at least weekly during maintenance (trough targets by FPIA: at least 15 mg/L for complicated skin and soft-tissue infection, pneumonia and complicated urinary tract infection; above 20 mg/L for bone and joint infection; 30–40 mg/L after loading and above 30 mg/L during maintenance for endocarditis). In kidney impairment, set the day-4 reduction by trough rather than by CrCl alone. Kidney function closely in CKD, after high loading doses and with nephrotoxic drugs. Hearing tests with ototoxic or nephrotoxic co-medication. Blood counts periodically (SmPC 4.4). Kidney
- Trough levels after loading and at least weekly
- Kidney function, especially with high loading doses or nephrotoxic drugs
- Hearing with ototoxic co-medication
- Blood counts periodically
Pharmacokinetics
Key PK parameters
| Bioavailability | Not absorbed orally (oral use is for colitis only) |
|---|---|
| Half-life | Terminal 100 to 170 hours |
| Half-life in kidney failure (ESKD) kidney | Prolonged; clearance tracks creatinine clearance (not quantified) |
| Volume of distribution | 0.7 to 1.4 L/kg (steady state) |
| Protein binding | 87.6% to 90.8% (albumin) |
| Metabolism (CYP, transporters) | Minimal (2% to 3% hydroxylated) |
| Renal excretion kidney | About 80% unchanged in urine over 16 days |
| Dialyzability kidney | Not removed by hemodialysis; slowly by peritoneal dialysis |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Swedish Medical Products Agency. Targocid powder for solution for injection/infusion SmPC (English) [MPA (Sweden) product information, December 11, 2025; no US FDA label]. https://docetp.mpa.se/LMF/Targocid%20powder%20for%20solution%20for%20injection%20or%20infusion%20ENG%20SmPC_09001bee84dd93a5.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Sanofi. (2025). Targocid 200 mg and 400 mg powder for solution for injection/infusion or oral solution (teicoplanin) [Summary of product characteristics, English; revised December 11, 2025]. Swedish Medical Products Agency (Läkemedelsverket). https://docetp.mpa.se/LMF/Targocid%20powder%20for%20solution%20for%20injection%20or%20infusion%20ENG%20SmPC_09001bee84dd93a5.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .